Publications

Publications (9)

A Cambridge, Mass., company, Semma Therapeutics, has acquired Providence-based CytoSolv, Inc., which has garnered local support since its founding in 2010 from the Slater Technology Fund and others, Slater announced Monday.
Read more
Semma aims to create a beta cell device implant for Type 1 diabetes patients that could provide them with 5 to 7 years of insulin independence. The notion of beta cell replacement therapy is not…
Read more
When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. “I remember at night, my wife and I pricking his heel, and saying ‘No, this can’t…
Read more
Semma Therapeutics Inc. has raised $114 million in a series B financing aimed at carrying its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes, through proof-of-concept studies. The company…
Read more
VIDEO - JDRF Boston Gala: Nancy Jones Diabetes Champion Award Recipient, Semma Therapeutics
Read more